Showing 2642 results
- Media Release /Multi-year investment of USD 300m will create integrated scientific environment to deliver on increasing growth and diversity of biotherapeutics portfolio Enhanced capacity and processes…
- Media Release /RATIONALE 301 trial met its objective at final analysis, demonstrating non-inferior overall survival (OS) for tislelizumab (median OS: 15.9 months) versus sorafenib (median OS: 14.1 months) in…
- Media Release /Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and…
- Featured News /
AI offers the greatest potential to transform health systems from being reactive to proactive, predictive, and even preventive.
- Story /
Genome editing advances drug discovery in biomedical research.
- Story /
Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model
- Story /
A cellular computing error wreaks havoc on vision.
- Media Release /Kymriah offers patients in Europe with advanced follicular lymphoma a potentially definitive, single infusion CAR-T cell therapy with a remarkable safety profile Approval based on the Phase II…
- Media Release /With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for…
Pagination
- ‹ Previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- …
- 265
- › Next page